Researchers found that fewer dupilumab-receiving patients had high mucus plug scores at week 24 than at baseline (32.8 vs 67.2%). HealthDay News — Dupilumab reduces mucus plug scores and improves lung ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Dupilumab for uncontrolled asthma improved mucus ...

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, most often caused by cigarette smoking or long-term exposure to air pollutants. While there is ...

WASHINGTON -- Dupilumab (Dupixent) reduced airway inflammation and increased lung capacity in patients with uncontrolled, moderate-to-severe asthma, while also reducing troublesome mucus plugs, a ...

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, most often caused by cigarette smoking or long-term exposure to air pollutants. While there is ...

Dupilumab (Dupixent), an interleukin (IL)-4/IL-13-blocking antibody, significantly reduced nitric oxide levels compared to placebo and reduced mucus plug scores by as early as 4 weeks, according to a ...

A retrospective analysis of data of patients with chronic obstructive pulmonary disease (COPD) suggests that mucus plugs could contribute to patient mortality, offering a possible treatment target.

Researchers may have found a new target in chronic obstructive pulmonary disease (COPD) symptoms that could potentially save more lives. The study focused on mucus plugs, which clog airways in the ...

Please provide your email address to receive an email when new articles are posted on . 58% of patients had at least one mucus plug. Patients with four or more mucus plugs had a median FEV 1 of about ...